Back Article

  • Acuna R, Cifuentes-Munoz N, Marquez CL, Bulling M, Kling-strom J, Mancini R, Lozach PY, Tischler ND, 2014: Hantavirus Gn and Gc glycoproteins self-assemble into virus-like particles[J]. J Virol, 88, 2344-2348. doi: 10.1128/JVI.03118-13

  • Akahata W, Yang ZY, Andersen H, Sun S, Holdaway HA, Kong WP, Lewis MG, Higgs S, Rossmann MG, Rao S, Nabel GJ, 2010: A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection[J]. Nat Med, 16, 334-338. doi: 10.1038/nm.2105

  • Atmar RL, Bernstein DI, Harro CD, Al-Ibrahim MS, Chen WH, Ferreira J, Estes MK, Graham DY, Opekun AR, Richardson C, Mendelman PM, 2011: Norovirus Vaccine against Experimental Human Norwalk Virus Illness[J]. New Engl J Med, 365, 2178-2187. doi: 10.1056/NEJMoa1101245

  • Bai B, Hu Q, Hu H, Zhou P, Shi Z, Meng J, Lu B, Huang Y, Mao P, Wang H, 2008: Virus-like particles of SARS-like coronavir-us formed by membrane proteins from different origins demon-strate stimulating activity in human dendritic cells[J]. PLoS One, 3, e2685-. doi: 10.1371/journal.pone.0002685

  • Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magas-souba N, Soropogui B, Sow MS, Keita S, De Clerck H, Tiffany A, Dominguez G, Loua M, Traore A, Kolie M, Malano ER, Heleze E, Bocquin A, Mely S, Raoul H, Caro V, Cadar D, Gabriel M, Pahlmann M, Tappe D, Schmidt-Chanasit J, Impouma B, Diallo AK, Formenty P, Van Herp M, Gunther S, 2014: Emergence of Zaire Ebola virus disease in Guinea[J]. N Engl J Med, 371, 1418-1425. doi: 10.1056/NEJMoa1404505

  • Ball JM, Estes MK, Hardy ME, Conner ME, Opekun AR, Graham DY, 1996: Recombinant Norwalk virus-like particles as an oral vaccine[J]. Arch Virol, Suppl 12, 243-249.

  • Ball JM, Hardy ME, Atmar RL, Conner ME, Estes MK, 1998: Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice[J]. J Virol, 72, 1345-1353.

  • Branco LM, Grove JN, Geske FJ, Boisen ML, Muncy IJ, Magliato SA, Henderson LA, Schoepp RJ, Cashman KA, Hensley LE, Garry RF, 2010: Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever[J]. Virol J, 7, 279-. doi: 10.1186/1743-422X-7-279

  • Bright RA, Carter DM, Crevar CJ, Toapanta FR, Steckbeck JD, Cole KS, Kumar NM, Pushko P, Smith G, Tumpey TM, Ross TM, 2008: Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle[J]. PLoS One, 3, e1501-. doi: 10.1371/journal.pone.0001501

  • Buonaguro L, Tagliamonte M, Tornesello ML, Buonaguro FM, 2011: Developments in virus-like particle-based vaccines for in-fectious diseases and cancer[J]. Expert Rev Vaccines, 10, 1569-1583. doi: 10.1586/erv.11.135

  • Buonaguro L, Visciano ML, Tornesello ML, Tagliamonte M, Biryahwaho B, Buonaguro FM, 2005: Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation[J]. J Virol, 79, 7059-7067. doi: 10.1128/JVI.79.11.7059-7067.2005

  • Chackerian B, Lenz P, Lowy DR, Schiller JT, 2002: Determinants of autoantibody induction by conjugated papillomavirus virus-like particles[J]. J Immunol, 169, 6120-6126. doi: 10.4049/jimmunol.169.11.6120

  • Cox RG, Erickson JJ, Hastings AK, Becker JC, Johnson M, Craven RE, Tollefson SJ, Boyd KL, Williams JV, 2014: Human metapneumovirus virus-like particles induce protective B and T cell responses in a mouse model[J]. J Virol, 88, 6368-6379. doi: 10.1128/JVI.00332-14

  • D'Aoust MA, Couture MM, Charland N, Trepanier S, Landry N, Ors F, Vezina LP, 2010: The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza[J]. Plant Biotechnol J, 8, 607-619. doi: 10.1111/j.1467-7652.2009.00496.x

  • de Groot RJ, Baker SC, Baric RS, Brown CS, Drosten C, Enjuanes L, Fouchier RAM, Galiano M, Gorbalenya AE, Memish ZA, Perlman S, Poon LLM, Snijder EJ, Stephens GM, Woo PCY, Zaki AM, Zambon M, Ziebuhr J, 2013: Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group[J]. J Virol, 87, 7790-7792. doi: 10.1128/JVI.01244-13

  • Du R, Yin F, Wang M, Hu Z, Wang H, Deng F, 2015: Glycoprotein E of the Japanese encephalitis virus forms virus-like particles and induces syncytia when expressed by a baculovirus[J]. J Gen Virol, 96, 1006-1014. doi: 10.1099/vir.0.000052

  • El-Kamary SS, Pasetti MF, Mendelman PM, Frey SE, Bernstein DI, Treanor JJ, Ferreira J, Chen WH, Sublett R, Richardson C, Bargatze RF, Sztein MB, Tacket CO, 2010: Adjuvanted Intranasal Norwalk Virus-Like Particle Vaccine Elicits Antibodies and Antibody-Secreting Cells That Express Homing Receptors for Mucosal and Peripheral Lymphoid Tissues[J]. J Infect Dis, 202, 1649-1658. doi: 10.1086/653023

  • Garcia-Sastre A, Mena I, 2013: Novel vaccine strategies against emerging viruses[J]. Curr Opin Virol, 3, 210-216. doi: 10.1016/j.coviro.2013.02.001

  • Harrington PR, Yount B, Johnston RE, Davis N, Moe C, Baric RS, 2002: Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles[J]. J Virol, 76, 730-742. doi: 10.1128/JVI.76.2.730-742.2002

  • Harrison MS, Sakaguchi T, Schmitt AP, 2010: Paramyxovirus as-sembly and budding: building particles that transmit infections[J]. Int J Biochem Cell Biol, 42, 1416-1429. doi: 10.1016/j.biocel.2010.04.005

  • Herbst-Kralovetz M, Mason HS, Chen Q, 2010: Norwalk virus-like particles as vaccines[J]. Expert Rev Vaccines, 9, 299-307. doi: 10.1586/erv.09.163

  • Holmes DA, Purdy DE, Chao DY, Noga AJ, Chang GJ, 2005: Comparative analysis of immunoglobulin M (IgM) capture enzyme-linked immunosorbent assay using virus-like particles or virus-infected mouse brain antigens to detect IgM antibody in sera from patients with evident flaviviral infections[J]. J Clin Microbiol, 43, 3227-3236. doi: 10.1128/JCM.43.7.3227-3236.2005

  • Kang SM, Song JM, Quan FS, Compans RW, 2009: Influenza vaccines based on virus-like particles[J]. Virus Res, 143, 140-146. doi: 10.1016/j.virusres.2009.04.005

  • Khurana S, Wu J, Verma N, Verma S, Raghunandan R, Manischewitz J, King LR, Kpamegan E, Pincus S, Smith G, Glenn G, Golding H, 2011: H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans[J]. J Virol, 85, 10945-10954. doi: 10.1128/JVI.05406-11

  • Kong D, Wen Z, Su H, Ge J, Chen W, Wang X, Wu C, Yang C, Chen H, Bu Z, 2012: Newcastle disease virus-vectored Nipah encephalitis vaccines induce B and T cell responses in mice and long-lasting neutralizing antibodies in pigs[J]. Virology, 432, 327-335. doi: 10.1016/j.virol.2012.06.001

  • L'Vov D K, Al'khovskii SV, Shchelkanov M, Shchetinin AM, De-riabin PG, Aristova VA, Gitel'man AK, Samokhvalov EI, Botikov AG, 2014: Taxonomic status of the Tyulek virus (TLKV) (Orthomyxoviridae, Quaranjavirus, Quaranfil group) isolated from the ticks Argas vulgaris Filippova, 1961 (Argasidae) from the birds burrow nest biotopes in the Kyrgyzstan[J]. Vopr Virusol, 59, 28-32.

  • López-Macías C, Ferat-Osorio E, Tenorio-Calvo A, Isibasi A, Ta-lavera J, Arteaga-Ruiz O, Arriaga-Pizano L, Hickman SP, Al-lende M, Lenhard K, Pincus S, Connolly K, Raghunandan R, Smith G, Glenn G, 2011: Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mex-ico[J]. Vaccine, 29, 7826-7834. doi: 10.1016/j.vaccine.2011.07.099

  • Landry N, Ward BJ, Trépanier S, Montomoli E, Dargis M, Lapini G, Vézina L-P, 2010: Preclinical and Clinical Development of Plant-Made Virus-Like Particle Vaccine against Avian H5N1 Influenza[J]. PLoS One, 5, e15559-. doi: 10.1371/journal.pone.0015559

  • Li C, Liu F, Liang M, Zhang Q, Wang X, Wang T, Li J, Li D, 2010: Hantavirus-like particles generated in CHO cells induce specific immune responses in C57BL/6 mice[J]. Vaccine, 28, 4294-4300. doi: 10.1016/j.vaccine.2010.04.025

  • Lindesmith LC, Ferris MT, Mullan CW, Ferreira J, Debbink K, Swanstrom J, Richardson C, Goodwin RR, Baehner F, Mendel-man PM, Bargatze RF, Baric RS, 2015: Broad Blockade Anti-body Responses in Human Volunteers after Immunization with a Multivalent Norovirus VLP Candidate Vaccine: Immunological Analyses from a Phase Ⅰ Clinical Trial[J]. PLoS Med, 12, 32-.

  • Liu Y, Zhou J, Yu Z, Fang D, Fu C, Zhu X, He Z, Yan H, Jiang L, 2014: Tetravalent recombinant dengue virus-like particles as po-tential vaccine candidates: immunological properties[J]. BMC Microbiol, 14, 233-. doi: 10.1186/s12866-014-0233-3

  • Lu B, Huang Y, Huang L, Li B, Zheng Z, Chen Z, Chen J, Hu Q, Wang H, 2010: Effect of mucosal and systemic immunization with virus-like particles of severe acute respiratory syndrome coronavirus in mice[J]. Immunology, 130, 254-261. doi: 10.1111/imm.2010.130.issue-2

  • Mandell RB, Koukuntla R, Mogler LJ, Carzoli AK, Freiberg AN, Holbrook MR, Martin BK, Staplin WR, Vahanian NN, Link CJ, Flick R, 2010: A replication-incompetent Rift Valley fever vac-cine: chimeric virus-like particles protect mice and rats against lethal challenge[J]. Virology, 397, 187-198. doi: 10.1016/j.virol.2009.11.001

  • Mani S, Tripathi L, Raut R, Tyagi P, Arora U, Barman T, Sood R, Galav A, Wahala W, de Silva A, Swaminathan S, Khanna N, 2013: Pichia pastoris-expressed dengue 2 envelope forms virus-like particles without pre-membrane protein and induces high titer neutralizing antibodies[J]. PLoS One, 8, e64595-. doi: 10.1371/journal.pone.0064595

  • McGinnes LW, Gravel KA, Finberg RW, Kurt-Jones EA, Massare MJ, Smith G, Schmidt MR, Morrison TG, 2011: Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G pro-teins[J]. J Virol, 85, 366-377. doi: 10.1128/JVI.01861-10

  • Metz SW, Gardner J, Geertsema C, Le TT, Goh L, Vlak JM, Suhr-bier A, Pijlman GP, 2013: Effective chikungunya virus-like particle vaccine produced in insect cells[J]. PLoS Negl Trop Dis, 7, e2124-. doi: 10.1371/journal.pntd.0002124

  • Moore MD, Goulter RM, Jaykus LA, 2015: Human norovirus as a foodborne pathogen: challenges and developments[J]. Annu Rev Food Sci Technol, 6, 411-433. doi: 10.1146/annurev-food-022814-015643

  • Mortola E, Roy P, 2004: Efficient assembly and release of SARS coronavirus-like particles by a heterologous expression system[J]. FEBS Lett, 576, 174-178. doi: 10.1016/j.febslet.2004.09.009

  • Noranate N, Takeda N, Chetanachan P, Sittisaman P, AN A, Anantapreecha S, 2014: Characterization of chikungunya virus-like particles[J]. PLoS One, 9, e108169-. doi: 10.1371/journal.pone.0108169

  • Oldstone MBA, 2002: Arenaviruses Ⅰ-The epidemiology, molecu-lar and cell biology of arenaviruses -Preface[J]. Arenaviruses Ⅰ, 262, Ⅴ-Ⅹⅱ.

  • Overby AK, Popov V, Neve EP, Pettersson RF, 2006: Generation and analysis of infectious virus-like particles of uukuniemi virus (bunyaviridae): a useful system for studying bunyaviral pack-aging and budding[J]. J Virol, 80, 10428-10435. doi: 10.1128/JVI.01362-06

  • Patel MM, Hall AJ, Vinje J, Parashara UD, 2009: Noroviruses: A comprehensive review[J]. J Clin Virol, 44, 1-8. doi: 10.1016/j.jcv.2008.10.009

  • Purdy DE, Chang GJ, 2005: Secretion of noninfectious dengue virus-like particles and identification of amino acids in the stem region involved in intracellular retention of envelope protein[J]. Virology, 333, 239-250. doi: 10.1016/j.virol.2004.12.036

  • Quan FS, Huang C, Compans RW, Kang SM, 2007: Virus-like particle vaccine induces protective immunity against homolog-ous and heterologous strains of influenza virus[J]. J Virol, 81, 3514-3524. doi: 10.1128/JVI.02052-06

  • Quan FS, Kim Y, Lee S, Yi H, Kang SM, Bozja J, Moore ML, Compans RW, 2011: Viruslike particle vaccine induces protec-tion against respiratory syncytial virus infection in mice[J]. J Infect Dis, 204, 987-995. doi: 10.1093/infdis/jir474

  • Ramani S, Atmar RL, Estes MK, 2014: Epidemiology of human noroviruses and updates on vaccine development[J]. Curr Opin Gastroenterol, 30, 25-33. doi: 10.1097/MOG.0000000000000022

  • Rodriguez-Limas WA, Sekar K, Tyo KE, 2013: Virus-like particles: the future of microbial factories and cell-free systems as platforms for vaccine development[J]. Curr Opin Biotechnol, 24, 1089-1093. doi: 10.1016/j.copbio.2013.02.008

  • Roldão A, Mellado MCM, Castilho LR, Carrondo MJT, Alves PM, 2010: Virus-like particles in vaccine development[J]. Expert Rev Vaccines, 9, 1149-1176. doi: 10.1586/erv.10.115

  • Schmeisser F, Adamo JE, Blumberg B, Friedman R, Muller J, Soto J, Weir JP, 2012: Production and characterization of mammalian virus-like particles from modified vaccinia virus Ankara vectors expressing influenza H5N1 hemagglutinin and neuraminidase[J]. Vaccine, 30, 3413-3422. doi: 10.1016/j.vaccine.2012.03.033

  • Schweitzer BK, Chapman NM, Iwen PC, 2009: Overview of the Flaviviridae With an Emphasis on the Japanese Encephalitis Group Viruses[J]. Lab Medicine, 40, 493-499. doi: 10.1309/LM5YWS85NJPCWESW

  • Scotti N, Rybicki EP, 2013: Virus-like particles produced in plants as potential vaccines[J]. Expert Rev Vaccines, 12, 211-224. doi: 10.1586/erv.12.147

  • Singh G, Kumar A, Singh K, Kaur J, 2015: Ebola virus: an intro-duction and its pathology[J]. Rev Med Virol, , -. doi: 10.1002/rmv.1863

  • Staples JE, Breiman RF, Powers AM, 2009: Chikungunya fever: an epidemiological review of a re-emerging infectious disease[J]. Clin Infect Dis, 49, 942-948. doi: 10.1086/599189

  • Strecker T, Eichler R, Meulen Jt, Weissenhorn W, Dieter Klenk H, Garten W, Lenz O, 2003: Lassa virus Z protein is a matrix pro-tein sufficient for the release of virus-like particles[J]. J Virol, 77, 10700-10705. doi: 10.1128/JVI.77.19.10700-10705.2003

  • Swayne DE, Suarez DL, 2000: Highly pathogenic avian influenza[J]. Rev Sci Tech, 19, 463-482. doi: 10.20506/rst.issue.19.2.14

  • Swenson DL, Warfield KL, Kuehl K, Larsen T, Hevey MC, Schmaljohn A, Bavari S, Aman MJ, 2004: Generation of Mar-burg virus-like particles by co-expression of glycoprotein and matrix protein[J]. FEMS Immunol Med Microbiol, 40, 27-31. doi: 10.1016/S0928-8244(03)00273-6

  • Wagner R, Deml L, Schirmbeck R, Reimann J, Wolf H, 1994: In-duction of a MHC class Ⅰ-restricted, CD8 positive cytolytic T-cell response by chimeric HIV-1 virus-like particles in vivo: im-plications on HIV vaccine development[J]. Behring Inst Mitt, 95, 23-34.

  • Walpita P, Barr J, Sherman M, Basler CF, Wang L, 2011: Vaccine Potential of Nipah Virus-Like Particles[J]. PLoS One, 6, e18437-. doi: 10.1371/journal.pone.0018437

  • Warfield KL, Aman MJ, 2011: Advances in virus-like particle vaccines for filoviruses[J]. J Infect Dis, 204, S1053-S1059. doi: 10.1093/infdis/jir346

  • Warfield KL, Bosio CM, Welcher BC, Deal EM, Mohamadzadeh M, Schmaljohn A, Aman MJ, Bavari S, 2003: Ebola virus-like particles protect from lethal Ebola virus infection[J]. Proc Natl Acad Sci U S A, 100, 15889-15894. doi: 10.1073/pnas.2237038100

  • Warfield KL, Posten NA, Swenson DL, Olinger GG, Esposito D, Gillette WK, Hopkins RF, Costantino J, Panchal RG, Hartley JL, Aman MJ, Bavari S, 2007: Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents[J]. J Infect Dis, 196, S421-S429.

  • WHO 2015. Ebola Situation Report 21 Oct 2015. http://apps.who. int/iris/bitstream/10665/190067/1/ebolasitrep_21Oct2015_eng.pdf

  • WHO 2016. Middle East respiratory syndrome coronavirus (MERS-CoV) -Saudi Arabia. 22 June 2016. http://www.who.int/csr/don/ 22-june-2016-mers-saudi-arabia/en/

  • Yamaji H, Nakamura M, Kuwahara M, Takahashi Y, Katsuda T, Konishi E, 2013: Efficient production of Japanese encephalitis virus-like particles by recombinant lepidopteran insect cells[J]. Appl Microbiol Biotechnol, 97, 1071-1079. doi: 10.1007/s00253-012-4371-y

  • Yang L, Song Y, Li X, Huang X, Liu J, Ding H, Zhu P, Zhou P, 2012: HIV-1 virus-like particles produced by stably transfected Drosophila S2 cells: a desirable vaccine component[J]. J Virol, 86, 7662-7676. doi: 10.1128/JVI.07164-11

  • Zeltins A, 2013: Construction and characterization of virus-like particles: a review[J]. Mol Biotechnol, 53, 92-107. doi: 10.1007/s12033-012-9598-4

  • Zhang S, Liang M, Gu W, Li C, Miao F, Wang X, Jin C, Zhang L, Zhang F, Zhang Q, Jiang L, Li M, Li D, 2011: Vaccination with dengue virus-like particles induces humoral and cellular immune responses in mice[J]. Virol J, 8, 333-. doi: 10.1186/1743-422X-8-333

  • Zhao Q, Li S, Yu H, Xia N, Modis Y, 2013: Virus-like particle-based human vaccines: quality assessment based on structural and functional properties[J]. Trends Biotechnol, 31, 654-663. doi: 10.1016/j.tibtech.2013.09.002

  • Zhou ZR, Wang ML, Deng F, Li TX, Hu ZH, Wang HL, 2011: Production of CCHF virus-like particle by a baculovirus-insect cell expression system[J]. Virol Sin, 26, 338-346. doi: 10.1007/s12250-011-3209-6